Working-age persons with multiple sclerosis and access to disease-modifying medications

Multiple Sclerosis

Volumn 14, Issue 1, 2008, Pages 112-122

  Lezzoni, L I ^a,b   Ngo, L H ^a   Kinkel, R P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Access; Disease modifying medications; Health insurance; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FUNDING; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRESCRIPTION; PUBLIC HEALTH INSURANCE; UNITED STATES; ECONOMICS; EMPLOYMENT; MEDICAID; MEDICARE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT; QUESTIONNAIRE; STATISTICAL MODEL; STATISTICS;

ADULT; EMPLOYMENT; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; IMMUNOLOGIC FACTORS; INSURANCE, HEALTH; INSURANCE, MEDIGAP; LOGISTIC MODELS; MALE; MEDICAID; MEDICALLY UNINSURED; MEDICARE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MULTIVARIATE ANALYSIS; QUESTIONNAIRES; UNITED STATES;

EID: 42149093772     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458507080466     Document Type: Article

References (39)

1. Wallack SS, Weinberg DB, Thomas CP. Health plans' strategies to control prescription drug spending. Health Aff 2004; 23: 141-8.
2. National Multiple Sclerosis Society. Comparing the disease-modifying drugs. New York: National Multiple Sclerosis Society, 2006. Retrieved from www.nationalmssociety.org/ Brochures-Comparing.asp, accessed 16 June 2006.
3. Calder K. Finding lower-priced prescription drugs. New York: National Multiple Sclerosis Society. Retrieved from www.nationalmssociety.org/healthinsurance_resources.asp, accessed 16 June 2006.
4. Iezzoni LI, Ngo L. Health, disability, and life insurance experiences of working-age persons with multiple sclerosis. Mult Scler 2007; 13: 534-46.
5. Minden SL, Frankel D, Hadden L, Perloff J, Srinath KP, Hoaglin DC. The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult Scler 2006; 12: 1-15.
6. Minden SL, Frankel D, Hadden LS, Srinath KP, Perloff JN. Disability in elderly people with multiple sclerosis: an analysis of baseline data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. NeuroRehabilitation 2004; 19: 55-67.
7. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998; 4: 419-25.
8. Roper Starch Worldwide, Inc. An analysis of non-members. Report prepared for the National Multiple Sclerosis Society. New York: Roper Starch Worldwide, Inc., 1998.
9. Adams PF, Marano MA. Current estimates from the National Health Interview Survey, 1994. National Center for Health Statistics. Vital Health Stat 1995; 10(193): 1-260.
10. Iezzoni LI, McCarthy EP, Davis RB, Siebens H. Access to health care and insurance for working-age adults reporting mobility difficulties. Res Soc Sci Disability 2003; 3: 131-55.
11. Cohen J. Design and methods of the Medical Expenditure Panel Survey Household Component. AHCPR Pub. No. 97-97-0026. Rockville, MD: Agency for Health Care Policy and Research, 1997.
12. Harris Interactive, Inc. 2000 National Organization on Disability/Harris Survey of Americans with Disabilities. Conducted for the National Organization on Disability. New York: Harris Interactive, Inc., 2000.
13. Hanson K, Neuman P, Voris M. Understanding the Health-Care Needs and Experiences of People with Disabilities. Findings from a 2003 Survey. Menlo Park, CA: The Henry J. Kaiser Family Foundation, 2003.
14. Hanson KW, Neuman P, Dutwin D, Kasper JD. Understanding the challenges facing people with disabilities: the role of health insurance. Health Aff Web Exclusive 2003 (19 November); W3-552.
15. Hsu J, Price M, Huang J, Brand R, Fung V, Hui R et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med 2006; 354: 2349-59.
16. Mohr DC, Goodkin DE, Likosky W, Gatto N, Neilley LK, Griffin C et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b; relationship to adherence to treatment. Mult Scler 1996; 2: 222-6.
17. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of b-interferons prescribed for MS. Neurology 2003; 61: 551-4.
18. Rio J, Porcel J, Tellez N, Sanchez-Betancourt A, Tintore M, Arevalo MJ et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005; 11: 306-9.
19. The CHAMPIONS Study Group. IM Interferon Beta 1a delays definite multiple sclerosis 5-years after a first demyelinating event. Neurology 2006; 66: 678-84.
20. Avorn J. Part "D" for "defective" - Medicare drug-benefit chaos. N Engl J Med 2006; 354: 1339-41.
21. Slaughter LM. Medicare Part D - the product of a broken process. N Engl J Med 2006; 354: 2314-15.
22. Crowley JS, Williams B. Navigating the Medicare Part D prescription drug coverage program. A guide for people with disabilities, benefits counselors, disability organizations and others on ensuring adequate and appropriate access to prescription drugs. Washington, DC: United Cerebral Palsy, 2006. Retrieved from www.ucp.org.
23. Stuart B, Briesacher BA, Shea DG, Cooper B, Baysac FS, Limcangco MR. Riding the rollercoaster: the ups and downs in out-of-pocket spending under the standard Medicare drug benefit. Health Aff 2005; 24(4): 1022-31.
24. Stuart B, Simoni-Wastila L, Chauncey D. Assessing the impact of coverage gaps in the Medicare Part D drug benefit. Health Aff Web Exclusive 2005 (19 April): W5-167-W5-179.
25. National Multiple Sclerosis Society. Medicare Rx Coverage. What are your options & costs? Retrieved from www.nationalmssociety.org/medicare_options.asp, accessed 15 June 2006.
26. Anderson GF, Shea DG, Hussey PS. Doughnut holes and price controls. Health Aff Web Exclusive 2004 (21 July). Retrieved from content.healthaffairs.org.
27. The Henry J. Kaiser Family Foundation. Voices of beneficiaries: early experiences with the Medicare drug benefit. Menlo Park, CA: The Henry J. Kaiser Family Foundation, Report #7504, April 2006. Retrieved from www.kff.org.
28. Confavreux C, Paty DW. Current status of computerization of multiple sclerosis clinical date for research in Europe and North America: the EDMUS/MS-COSTAR connection. Neurology 1995; 45: 573-6.
29. Jacobs LD, Wende KE, Brownscheidle CM, Apatoff B, Coyle PK, Goodman A et al. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler 1999; 5: 369-76.
30. Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH et al. Change in MS-related disability in a population-based cohort. A 10-year follow-up study. Neurology 2004; 62: 51-9.
31. Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology 2003; 61: 1373-77.
32. Anderson DW, Ellenberg JH, Leventhaol CM, Reingold SC, Rodriguez M, Silberberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992; 31: 333-6.
33. Krieger N, Chen JT, Waterman PD, Rehkopf DH, Subramanian SV. Painting a truer picture of US socioeconomic and racial/ethnic health inequalities: the Public Health Disparities Geocoding Project. Am J Public Health 2005; 95(2): 312-23.
34. Geronimus AT, Bound J. Use of census-based aggregate variables to proxy for socioeconomic group: evidence from national samples. Am J Epidemiol 1998; 148(5): 475-86.
35. Krieger N, Chen JT, Waterman PD, Rehkopf DH, Subramanian SV. Race/ ethnicity, gender, and monitoring socioeconomic gradients in health: a comparison of area-based socioeconomic measures-the public health disparities geocoding project. Am J Public Health 2003; 93(10): 1655-71.
36. Braveman PA, Cubbin C, Egerter S, Chideya S, Marchi KS, Metzler M et al. Socioeconomic status in health research: one size does not fit all. JAMA 2005; 294(22): 2879-88.
37. Clingerman E, Stuifbergen A, Becker H. The influence of resources on perceived functional limitations among women with multiple sclerosis. J Neurosci Nurs 2004; 36: 312-321.
38. Kraft GH. Improving health care delivery for persons with multiple sclerosis. Phys Med Rehabil Clin N Am 1998; 9: 703-15.
39. McLaughlin CM. Community programs and resources for persons with multiple sclerosis. Phys Med Rehabil Clin N Am 1998; 9: 689-702.